Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 4/20 | 0.46 |
| ▸ | GSK3A | P49840 | 2/20 | 0.46 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.45 |
| ▸ | ABL1 | P00519 | 11/20 | 0.44 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
| ▸ | CDK9 | P50750 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15051059 | 0.89 | JAK2 (0.40) | GSK3BGSK3APIK3C3JAK2JAK1 | |
| SCHEMBL15072351 | 0.88 | JAK2 (0.42) | GSK3BGSK3APIK3C3JAK2JAK1 | |
| SCHEMBL15051487 | 0.83 | ABL1 (0.47) | GSK3BGSK3AABL1 | |
| SCHEMBL15051720 | 0.83 | ABL1 (0.47) | GSK3BGSK3AABL1JAK2TYK2 | |
| SCHEMBL15051260 | 0.83 | JAK2 (0.39) | GSK3BGSK3APIK3C3JAK2JAK1 | |
| SCHEMBL15051049 | 0.81 | KDM4E (0.36) | — | |
| SCHEMBL15051164 | 0.76 | ABL1 (0.44) | GSK3BGSK3AABL1JAK2TYK2 | |
| SCHEMBL15051073 | 0.75 | JAK2 (0.40) | PIK3C3JAK2JAK1TYK2MAPK14 | |
| SCHEMBL15051121 | 0.74 | JAK2 (0.41) | GSK3BGSK3APIK3C3JAK2JAK1 | |
| SCHEMBL15050774 | 0.74 | KDM4E (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165464-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165464-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165464-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165464-A1 | HETEROARYLS AND USES THEREOF | PIK3C2B, PI4KB, PIK3R4 | GSK3B 539/4885GSK3A 1516/4885ACVRL1 2252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.